In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Panel discussion and conclusion - Current challenges and innovations in the treatment of mitral and tricuspid regurgitation.

Session Current challenges and innovations in the treatment of mitral and tricuspid regurgitation

Speaker Stefan Anker

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Treatment
  • Session type : Satellite Symposium
  • FP Number : 151
  • Organised by Charité Berlin, supported with an educational grant from Edwards
The ESC does not have the copyright for the slides and video of this presentation

Other presentations from this session

Current challenges and innovations in the treatment of mitral and tricuspid regurgitation

  • Heart Failure 2019 - 6th World Congress on Acute Heart Failure
  • Chronic Heart Failure - Treatment
  • Satellite Symposium
  • 25 May 2019
  • 13:30 - 14:30
session 2019 2019
6

Other presentations from this speaker

no speaker photo speaker

Stefan Anker

Charite - Campus Benjamin Franklin, Berlin (Germany)

110


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are